Increasing evidence has indicated that NAD + and NADH play critical roles not only in energy metabolism, but also in cell death and various cellular functions including regulation of calcium homeostasis and gene expression. It has also been indicated that NAD + and NADH are mediators of multiple major biological processes including aging. 
ABSTRACT
Increasing evidence has indicated that NAD + and NADH play critical roles not only in energy metabolism, but also in cell death and various cellular functions including regulation of calcium homeostasis and gene expression. It has also been indicated that NAD + and NADH are mediators of multiple major biological processes including aging. NAD + and NADH produce the biological effects by regulating numerous NAD + /NADH-dependent enzymes, including dehydrogenases, poly(ADP-ribose) polymerases, Sir2 family proteins (sirtuins), mono(ADP-ribosyl)transferases, and ADP-ribosyl cyclases. Of particular interest, NAD + -dependent generation of ADP-ribose, cyclic ADP-ribose and O-acetyl-ADP-ribose can mediate calcium homeostasis by affecting TRPM2 receptors and ryanodine receptors; and sirtuins and PARPs appear to play key roles in aging, cell death and a variety of cellular functions.
It has also been indicated that NADH and NAD + can be transported across plasma membranes of cells, and that extracellular NAD + may be a new signaling molecule. Our latest studies have shown that intranasal NAD + administration can profoundly decrease ischemic brain damage. These new pieces of information have fundamentally changed our understanding about NAD + and NADH, suggesting novel paradigms about the metabolism and biological activities of NAD + and NADH. Based on this information, it is tempted to hypothesize that NAD + and NADH, together with ATP and Ca
2+
, may be four most fundamental components in life, which can significantly affect nearly all major biological processes. Future studies on NAD + and NADH may not only elucidate some fundamental mysteries in biology, but also provide novel insights for interfering aging and many disease processes.
INTRODUCTION

NAD
+ and NADH have been long known as key co-factors in numerous dehydrogenase-mediated reactions (1). It has also been established that there are two pathways by which NAD + is synthesized: The salvage pathway and the de novo pathway (1). However, recent studies have provided numerous pieces of novel information about the metabolism and biological functions of NAD + and NADH, which are generalized in this review. This generalization may suggest new paradigms regarding the metabolism and the biological functions of NAD + and NADH, which could be of both theoretical and clinical significance.
Four major aspects about NAD + and NADH will be reviewed in this article: 1) NAD + and NADH metabolism; 2) biological functions of NAD + and NADH; 3) NAD + and NADH in cell death; and 4) therapeutic potential of NAD + . There are multiple new findings that are of particular significance. In the research field about NAD + and NADH metabolism, recent studies have suggested the existence of three isoforms of nicotinamide mononucleotide adenylyltransferases (NMNATs) ---the key enzymes for NAD + synthesis ---in cells with specific subcellular compartmentation. It has also been reported that NAD + and NADH can be transported across the plasma membranes of certain cell types by connexin43 hemichannels-or P2X 7 receptors-mediated mechanisms. The most exciting information regarding the biological functions of NAD + and NADH includes the findings indicating profound effects of NAD + -dependent histone acetylases, i.e., the Sir2 family proteins (sirtuins), on aging and gene expression. In the field about NAD + and NADH in cell death, significantly improved understanding about the roles of NAD + in poly(ADPribose) polymerase-1 (PARP-1)-mediated cell death has been achieved by recent studies; and multiple studies have also suggested new pathways by which NAD + and NADH can determine cell survival. Regarding the therapeutic potential of NAD + , the finding about the protective effects of NAD + administration on ischemic brain injury has raised the possibility that NAD + is a new agent for treating multiple PARP-1-associated diseases.
NAD + AND NADH METABOLISM IN CELLS
General information about NAD + and NADH in cells
The major biological activities of NAD + and NADH can be classified into four categories: First, in numerous redox reactions NAD + and NADH act as coenzymes (1). In these reactions NAD + and NADH is converted into each other, while the total pool of (NAD + + NADH) remains unchanged; second, NAD(P)H oxidase oxidizes NADH to NAD + with generation of reactive oxygen species (ROS), without changes of total pool of (NAD + + NADH); third, NAD + is catabolized into other nicotinamide-containing molecules through the actions of multiple NAD 
NAD
+ and NADH synthesis in cells As extensively reviewed by previous articles (8, 9), two well established NAD + biosynthesis pathways are the de novo pathway and the salvage pathway. A recent study suggests the presence of a new pathway: NADH can be directly generated from reduced form of nicotinamide mononucleotide (NMNH) and ATP by the actions of NMNATs (10), while the physiological significance of this new pathway has not been established.
The de novo pathway is required for NAD + generation when niacin availability is restricted (8, 9), through which mammals can synthesize nicotinamidecontaining nucleotides through the kynurenine pathway: L-Tryptophan is converted to L-kynurenine that is then converted to quinolinic acid.
Quinolinic acid is subsequently converted to nicotinate mononucleotide that is used for NAD + synthesis. In contrast, in the salvage pathway as well as the newly found pathway for NADH generation, NAD + and NADH are generated directly from nicotinamide-containing molecules (8-10). All of these three pathways converge to the common reversible reactions catalyzed by NMNATs, which generate NAD(H) plus PPi from NMN(H) and ATP (8-10). Because these reactions are fully reversible, NAD + can also be reconverted to ATP. This reversibility may have important biological implications:
ATP may be consumed to replete NAD + when NAD + is selectively depleted by such enzymes as PARP-1; vice versa, NAD + may also be consumed to regenerate ATP under the pathological conditions when ATP is selectively depleted.
While the nuclear enzyme NMNAT1 had been the only known NMNAT until recently, current studies have indicated presence of three isoforms of human NMNATs ---NMNAT1 -3 (9-11). In contrast to NMNAT1 that is a known nuclear enzyme, NMNAT2 and NMNAT3 may be localized in mitochondria and Golgi complex, respectively (9-11). The subcellular compartmentation of the three NMNATs suggests that there could be relatively independent NAD + synthesis machineries in these subcellular organelles (10). These findings could be critical for understanding the NAD + and NADH metabolism in the subcellular organelles (10), considering the reports suggesting the presence of tankyrase, a telomere-regulating PARP, in Golgi complex (12) and PARP activities in mitochondria (13).
In vitro studies have indicated that NMNAT1 could bind PARP-1 and inhibit PARP-1 activity (14 Our recent study has provided first evidence suggesting that NADH may be transported across plasma membranes into astrocytes: Treatment with 5 mM NADH significantly increased intracellular NAD + levels; and treatment with 10 µM -5 mM NADH after washout of the PARP activator and DNA alkylating agent MNNG significantly decreased astrocyte death (30). Our latest studies have used both molecular and pharmacological approaches to demonstrate that as low as 10 µM NADH can be transported into astrocytes through P2X 7 receptor (P2X 7 R)-mediated mechanisms (31). We found that incubation of murine astrocytes with 10 µM -10 mM of NADH significantly increased intracellular NAD + . Treatment with the purinergic (P2) receptor antagonists suramin and pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) prevented the NADH-produced increases in intracellular NAD + , suggesting that P2 receptors mediate the NADH transport. A critical role of P2X 7 R in the NADH transport is indicated by the findings that a reduction of P2X 7 R by RNA silencing led to decreased NADH transport, and transfection of P2X 7 R-deficient HEK293 cells with mouse P2X 7 R cDNA increased NADH transport. These observations collectively provide the first direct evidence demonstrating that NADH can be transported across the plasma membranes of cells. The observation that micromolar concentrations of extracellular NADH can be transported into astrocytes also suggests that the NADH transport may be involved in cell-cell signaling in brains. Future studies are warranted to determine if NADH can also be transported across the plasma membranes of other types of cells under both in vitro and in vivo conditions, and if the NADH transport is altered under various pathological conditions such as brain ischemia.
BIOLOGICAL FUNCTIONS OF NAD + AND NADH
While it has been long thought that the major cellular functions of NAD + and NADH are modulating cellular energy metabolism, increasing evidence has suggested that NAD + and NADH also play key roles in cell death (17, 23, 24) and various major cellular functions such as calcium homeostasis (22, 32) and gene expression (4, 33). Accumulating evidence has further indicated significant roles of NAD + and NADH in such important biological processes as aging, carcinogenesis and immunological functions (21, 32).
NAD
+ and NADH in energy metabolism NAD + and NADH levels significantly affect cellular energy metabolism via several pathways (1, 32): NAD + and NADH regulate glycolysis by acting as the cofactors for the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase; and NAD + and NADH mediate other important energy metabolism-related reactions occurring in cytosol, such as the lactate dehydrogenase-catalyzed lactate-pyruvate conversions. NAD + and NADH are also pivotal mediators of mitochondrial oxidative phosphorylation, because they are the co-factors for the three rate-limiting enzymes in mitochondrial tricarboxylic acid (TCA) cycle, and NADH is one of the major electron donors for electron transport chain (1). Recent studies have suggested novel mechanisms by which NAD + and NADH may modulate energy metabolism, e.g., NAD + may affect energy metabolism by regulating Sir2 family proteins, which can modulate acetyl-CoA synthetase and glycolysis / glycogenesis (34, 35) .
NAD + and NADH in mitochondrial functions
In addition to the well established roles of NAD + and NADH in the functioning of mitochondrial TCA cycle and electron transport chain, cumulative evidence suggests that NAD + and NADH can profoundly affect mitochondrial activities through other pathways: First, NAD + / NADH ratio is an important regulator of mitochondrial permeability transition (MPT) (36) . Second, NADH can directly interact with and inhibit voltage-dependent anion channels (VDAC), that controls the transport of small molecules across mitochondrial membranes and is a component of MPT pore (37) . The NADH-produced inhibition of VDAC opening suggests that abnormally increased cytosolic NADH may limit mitochondrial activity by blocking VDAC. Third, cytosolic NADH could be directly oxidized by cytochrome oxidase to increase mitochondrial membrane potential (38) . NAD + and NADH may also affect mitochondrial functions indirectly through other mechanisms, e.g., by modulating calcium homeostasis that is known to profoundly affect mitochondrial activities (39) ; and by regulating Sir2 family proteins that may affect Bax expression via modulating p53 activity (40, 41) .
NAD + and NADH mediate calcium homeostasis
Increasing evidence has suggested that both NAD + and NADH can mediate calcium homeostasis. NAD + may affect calcium homeostasis through the following pathways: First, ADP-ribosyl cyclases can generate cADPR from NAD + , which is a most potent endogenous agonist of ryanodine receptor-mediated calcium channels (42) . Second, recent studies have suggested that ADP-ribose, which could be generated from NAD + by NAD glycohydrolases or PARPs / poly(ADP-ribose) glycohydrolase (PARG), is an activator of TRPM2 receptors (43, 44). Third, Sir2 family proteins can generate O-acetyl-ADP-ribose that could be a novel signaling molecule: O-acetyl-ADPribose was found to directly bind the cytoplasmic domain of the TRPM2 channels and activate TRPM2 channels (45) . NAD + can further modulate calcium metabolism by promoting mono-ADP-ribosylation of P2X 7 R or through its conversion to NADP + by NAD + kinase: The ectoARTs-mediated mono-ADP-ribosylation of P2X 7 R has been shown to promote opening of P2X 7 R (46), which can lead to Ca 2+ influx (47); and NAADP generated from NADP + can also potently mobilize intracellular NAADP-dependent Ca 2+ stores (22, 48, 49).
The ecto-enzyme ADP-ribosyl cyclases or unidentified ADP-ribosyl cyclases located within the cytosol generate cADPR from NAD + in many cell types, which is a potent Ca 2+ mobilizing second messenger via activating type 2 and 3 ryanodine receptors (42, 49) . cADPR may activate ryanodine receptors by direct binding onto the receptors or by interacting with separate cADPR-binding proteins. Recent studies have suggested that cADPR can also affect calcium homeostasis by gating TRPM2 receptors (50) . Due to the important roles of ryanodine receptors and TRPM2 receptors in calcium homeostasis, it is expected the cADPR generation by ADP-ribosyl cyclases may profoundly modulate cellular functions and cell survival by mediating cellular calcium metabolism.
Cumulating evidence has demonstrated that transient receptor potential (TRP) family proteins play crucial roles in a variety of cellular functions (51, 52) . It has been indicated that TRPM7 receptors mediate NMDA-induced neurotoxicity (53, 54) ; and intracellular ADP-ribose appears to be an endogenous activator of TRPM2 (43, 44). The ADP-ribose / TRPM2 receptor pathways could mediate oxidative cell death by the following mechanisms (55-57): Oxidative damage causes PARP-1-induced PAR formation, leading to PARG-mediated generation of ADP-ribose that can produce opening of TRPM2 receptors, Ca 2+ influx and consequent cell death. (59) . It was also shown that NADH can inhibit ryanodine receptors of cardiac muscle, but not skeletal muscle (60, 61) , which could be mediated by the NADH oxidase activity of cardiac sarcoplasmic reticulum (62) . Figure 1 is a diagrammatic presentation showing the pathways by which NAD + and NADH affect calcium homeostasis. + is required for the activities of other PARPs such as tankyrases, which could also affect gene expression and genomic structure (64) . 3) Yeast Sir2 can silence transcription at telomeres and ribosomal DNA (65); sirtuins can also mediate the activities of such transcriptional factors as p53 and forkhead transcription factors (66); and mammalian Sir2 homolog SIRT7 was found to be an activator of RNA polymerase I transcription (67); and 4) NADH is a potent regulator of the activity of the corepressor carboxylterminal binding protein ---a transcriptional factor important for cell cycle regulation, development and transformation (4); and NADH also regulates the activities of Clock:BMAL1 and NPAS2:BMAL1, that are heterodimeric transcription factors controlling gene expression as a function of circadian clock (33).
Effects of NAD
NAD
+ and NADH in oxidative stress NAD + and NADH might affect the processes of aging and oxidative damage-mediated diseases due to its effect on cellular antioxidation capacity: NADH / NAD + ratio is an index of cellular reducing potential; and NAD + can be converted by NAD + kinase to NADP + ---the precursor for synthesizing the major reducing molecule NADPH (1). Seemingly paradoxically, excessive intracellular NADH can produce 'reductive stress', which may result from its capacity to induce release of ferrous iron from ferritin resulting in increased oxidative damage (68) . The 'reductive stress' may also result from the capacity of xanthine oxidase / xanthine dehydrogenase to generate ROS by oxidizing NADH (69).
Roles of NAD
+ and NADH in aging Cumulative evidence has suggested that NAD + and NADH could be critical factors in aging process by regulating sirtuins, PARP-1, tankyrases and oxidative stress. It has been suggested that Sir2 is a key enzyme mediating life span of yeast and C-elegans (21): A decrease or increase in gene copy of Sir2 shortens or extends the replicative life span of yeast, respectively (70); and increased gene copy of the Sir2 gene homolog in C-elegans also extends its life span (71) . It has been further suggested that calorie restriction modulates Sir2 activity and extends the life span of yeast by decreasing NADH levels (72) . Recently it was found that deficiency of SIRT6, a human homolog of Sir2, leads to aging-like phenotype and genomic instability in mice (73) . However, latest studies have suggested increasingly complicated roles of Sir2 in aging (74): While it increases replicative life span, Sir2 may decrease chronological life span of yeast at least under certain conditions (75). Thus, many future studies are still needed to further elucidate the complex effects of sirtuins on chronological and replicative life span of various species.
Telomere and telomerases have been indicated as key factors in cellular aging (76) . Since the NAD + -dependent tankyrases are mediators of telomerase activity (77), NAD + may also affect aging processes through tankyrases. It was reported that there is strong positive correlation between the PARP activities of mononuclear blood cells and the longevity of thirteen mammalian species, which may result from greater PARP-1-mediated DNA repair capacity (78, 79) . A role of PARP-1 in aging has been further raised by the recent report that PARP-1 interacts with and inhibits the catalytic activities of the protein of Werner syndrome ---a human disease of premature aging (80, 81). Because oxidative stress plays a critical role in aging process (82, 83) , NAD + and NADH may also affect aging through their influence on oxidative stress.
Roles of NAD + and NADH in carcinogenesis and cancer treatment
It has been reported that selective inhibition of NAD + synthesis can induce apoptosis of tumor cells (84). Because PARP-1 plays critical roles in regulating DNA repair, genomic stability, cell cycle progression and gene expression (17), extensive studies have been conducted to determine the roles of PARP-1 in carcinogenesis (85) . It has been found that PARP inhibitors can restore sensitivity of resistant tumors to methylating agents or topoisomerase I inhibitors, and may also decrease the toxic side effects of certain anticancer drugs (85) . Many studies have suggested important roles of telomerases and telomere in carcinogenesis (86) . Thus, NAD + -dependent tankyrases ---the enzymes that regulate telomerase activities (64, 87) ---may affect carcinogenesis by affecting telomere metabolism.
Increasing 89) . This study further raises the possibility that SIRT1 may be used as a target for cancer treatment. Intriguingly, this study also suggests a link among NAD + metabolism, carcinogenesis and aging: Aging-related decreases in HIC1 expression may promote carcinogenesis by producing increased SIRT1 activity and consequent inhibition of p53; and dietinduced increases in NAD + levels might also promote carcinogenesis by activating SIRT1 and inhibiting p53. Future studies are required to further investigate the associations among NAD + metabolism, sirtuins, aging and carcinogenesis, which could provide crucial information for understanding some of the most essential questions in biology. Due to the critical roles of NAD + and NADH in cell death and various cellular functions including gene expression and signal transduction, it is conceivable that future studies would further elucidate important roles of NAD + and NADH in carcinogenesis and cancer treatment.
NAD + and NADH in immunological functions
Recent studies have suggested that the ectoARTs can produce mono-ADP-ribosylation of P2X 7 R by consuming extracellular NAD + , thus significantly promoting opening of P2X 7 R. The P2X 7 R opening can lead to death of certain types of immune cells, particularly CD4+CD25+ T cells (Treg cells) ---a type of T cells that inhibit the activation of other types of T cells (46). Based on this information, it has been proposed that NAD + may be used to modulate immunological functions (46). A recent study has also indicated that cADPR is a second messenger mediating the lipopolysaccharide-induced proliferation of human peripheral blood mononuclear cells (90) . A number of recent studies have further indicated important roles of PARP-1 in inflammatory responses, due to its major effects on NF-κB (17). Since cell necrosis is a significant initiator of inflammatory responses and NAD + and NADH could determine cell death modes, NAD + and NADH may also significantly affect initiation of inflammatory responses. 
Biological functions of extracellular NAD +
Recent studies have indicated that extracellular NAD + may affect cellular functions by at least two mechanisms: First, extracellular NAD + can be used by the ecto-enzyme CD38, a human homolog of ADPribosyl cyclases, to generate cADPR, which is subsequently transported into cells by CD38 to act as a potent agonist of ryanodine receptor-gated calcium channels in astrocytes and other cell types (27, 28); and second, even 10 µM extracellular NAD + can produce T cell death, because ecto-ART2 can use NAD + to produce mono-ADP-ribosylation of P2X 7 R thus potently promoting its opening (46, 91). Collectively, these findings suggest that extracellular NAD + may be a novel extracellular messenger, particularly considering the significant biological effects of P2X 7 R and ryanodine receptor-gated calcium channels.
Summary of the biological activities of NAD + and NADH
Based on the discussions above, Figures 2 and 3 are drawn to provide diagrammatic presentations of the major biological activities of NAD + and NADH. It is noteworthy that much of the fundamental information supporting the diagrams is generated by recent studies, indicating that our knowledge about NAD + and NADH is undergoing an exciting, rapid growing phase. It is expected that these diagrams would be further evolving in the coming years.
NAD + AND NADH IN CELL DEATH
6.1. NAD + and NADH in PARP-1 toxicity 6.1.1. PARP-1 is a critical mediator of oxidative cell death both in vitro and in vivo Ischemia-reperfusion leads to extensive oxidative damage of proteins, phospholipids and DNA in the brains (92) (93) (94) . Oxidative stress has been indicated as a key mediator of ischemic brain damage (92, 95) . Excessive PARP-1 activation appears to mediate cell death induced by oxidative stress (96, 97) , NMDAinduced excitotoxicity (96) and oxygen-glucose deprivation (97) . In cerebral ischemia, PARP-1 activity is increased due to not only oxidative stress-induced DNA damage, but also oxidative stress-induced increases in PARP-1 expression (98) . Several lines of evidence have indicated that PARP-1 activation plays a key role in ischemic brain injury: First, increased PARP activities have been found in animal models of cerebral ischemia (99, 100) , and in human brains after cardiac arrest (101); second, both pharmacological and genetic inhibition of PARP-1 decreases infarct size by up to 80% in the brains subjected to transient or permanent ischemia (97, 100); and third, PARP inhibition can produce long-term beneficial effects on experimental stroke recovery (102) . These findings, combined with the findings indicating critical roles of PARP-1 in oxidative cell death in vitro and in ischemic damage of other organs (103) , demonstrate that PARP-1 mediates ischemic brain injury. Figure 4 is a diagrammatic presentation of the roles of PARP-1 in ischemic brain damage.
A number of studies have indicated that oxidative stress plays a significant role in the pathogenesis of Parkinson's disease (PD) (83, 104, 105) . Oxidative damage has also been indicated as one of the pathogenic factors in Alzheimer's disease (AD) (106) (107) (108) (109) (110) . Thus, it is conceivable that PARP-1 may mediate neuronal injury in PD and AD. PARP-1 activation appears to play a key role in the neuronal death induced by MPTP, a model toxin for PD, in both cell culture studies (111, 112) and in animal model studies (113) (114) (115) . Increased nuclear PARP activity has also been found in the brains and peripheral cells of AD patients (114, 116) . Recent studies have suggested that PARP-1 activation also mediates the β-amyloid-induced neuronal death, which is an in vitro model for AD (57, 117) . Cumulative evidence has further indicated that PARP-1 activation is an important pathological factor in traumatic brain injury (118) , diabetes (119), hypoglycemic brain injury (120) , and shock and inflammation (17, 103). PARP-1 has become a promising therapeutic target for multiple diseases (17, 103, 121).
Mechanisms of PARP-1-mediated cell death
While it has been long hypothesized that PARP-1 induces cell death by depleting NAD + and ATP (122) , not until recently there has been no direct demonstration of this hypothesis. Two recent studies have, by directly delivering NAD + into astrocytes, provided evidence demonstrating that NAD + depletion is a key step mediating PARP-1-induced cell death (24, 29). This finding, together with the report that liposomal NAD + delivery can partially prevent peroxynitriteinduced mitochondrial depolarization (13), indicates a key role of NAD + depletion in PARP-1-mediated cytotoxicity. Several studies have also shown that MPT (24) and apoptosis inducing factor (AIF) translocation (123) are important steps leading from NAD + depletion to cell death. There has also been information suggesting the mechanisms linking NAD + depletion and mitochondrial damage: NAD + depletion could mediate PARP-1-induced glycolytic inhibition (29), which would decrease pyruvate supply to TCA cycle thus reducing mitochondrial transmembrane H + gradient; and supply of TCA cycle substrates prevented PARP-1-induced neuronal and astrocyte death (124) . Based on these studies, we propose a new diagram regarding the mechanisms of PARP-1-induced cytotoxicity ( Figure 5 ).
Recent studies have also suggested other novel mechanisms underlying PARP-1 cytotoxicity. It was reported that ADP-ribose generated by PARP-1/PARG can produce TRPM2 opening, leading to increased intracellular calcium concentrations and cell death (55) (56) (57) . It was also suggested that SIRT1 is an essential link between NAD + depletion and cell death (125) . A latest study has further indicated significant interactions between PARP-1 and SIRT1: SIRT1 deficiency leads to significant increases in PARP-1 activity, resulting in AIF-mediated cell death (126) . While there have been multiple seemingly diverse mechanisms regarding PARP-1 toxicity, future studies may elucidate a common pathway linking these mechanisms. However, like the existence of diverse apoptotic cascades, there may also be differential PARP-1-mediated cell death cascades that are selectively activated depending on intensity of insults and cell types.
Several recent studies have indicated that PARP-1 inhibition produced completely different effects on the ischemic brain damage in male and female animals: While it profoundly decreased brain injury in male mice, PARP-1 inhibition markedly exacerbated ischemic brain damage in female mice (127) (128) (129) . These results could have significant clinical implications: Gender may be considered an important factor for design of therapeutic strategies for ischemic stroke and possibly other diseases.
The mechanisms underlying these intriguing findings still remain unclear. However, due to the critical roles of NAD + metabolism in PARP-1 toxicity, NAD + might be an important factor in the effects of gender on the brain injury.
Roles of PARG in cell survival
PARP-1-generated poly(ADP-ribose) (PAR) is rapidly degraded by the pivotal PAR-catabolizing enzyme PARG, resulting a half life of PAR less than 1 min (130) . PARG digests PAR into ADP-ribose, which is then rapidly converted to AMP by a Mg 2+ -dependent activity (131) . PARG is an endo-exoglycosidase existing in low abundance in cells, which has little homology to known proteins. Due to the indispensable role of PARG in modulating poly(ADP-ribosyl)ation (130), it is not surprising that several studies have suggested that PARG plays significant roles in regulating gene expression, cell cycle and cell differentiation (132) (133) (134) . -dependent endonucleases (CME) mediate DNA fragmentation in certain apoptotic cascade (137) . It has been found that CME is a substrate of PARP-1, and poly(ADP-ribosy)lation of CME leads to CME inhibition (137, 138) . Thus, PARG inhibition could prevent removal of PAR from CME, leading to persistent CME inhibition. Recent studies have also provided novel potential mechanisms underlying the protective effects of PARG inhibition: PARP-1/PARG activities can generate ADP-ribose from hydrolysis of PAR, leading to activation of TRPM2 receptors and consequent cell death (55) (56) (57) .
A number of in vitro and in vivo studies have supported the hypothesis that PARG may be a new target for decreasing oxidative cell death and ischemic tissue injuries (139) : First, the mice that have genetic deletion of the 110 kDa PARG isoform have significantly decreased ischemic damage of intestine (140) and kidney (141) compared with wild type mice. Second, treatment with novel PARG inhibitors can decrease ischemic injury of brain (142) and intestine (140) and reduce development of septic shock-like syndrome (143) . 3) PARG inhibitors can decrease death of various types of cells induced by oxidative stress and other PARP activators (135, 136, (144) (145) (146) . 4) Decreases of PARG levels by antisense oligonucleotide treatment (147) or RNA silencing (148) led to reduced PARP-1-mediated cell death. However, complete genetic deletion of PARG was reported to produce embryonic lethality of mice (149) . Collectively, the studies regarding the roles of PARG in cell survival suggest that only partial inhibition of PARG could be beneficial. Increasing evidence has indicated that PARG has highly complicated properties (139, 150) . Thus, extensive future studies are needed for elucidating the roles of PARG in cell survival.
Roles of other PARPs in cell death
A recent study has shown that overexpression of tankyrase 2 can cause rapid cell death (151) . It has also been indicated that PARP-2 is a new executioner of cell death in focal cerebral ischemia, while it can decrease hippocampal injury after global ischemia (152) . These studies suggest that in addition to PARP-1, other PARPs could also mediate cell death, and that the results obtained by using such non-specific PARP inhibitors as 3-aminobenzamide should be interpreted cautiously.
Important roles of the interactions among PARP-1, caspase-3 and calpains in determinations of cell death modes
Caspase-3 is one of the pivotal components in apoptotic cascades (153) (154) (155) .
Important roles of calpains in both apoptosis and necrosis have also been strongly indicated (156) . In contrast, PARP-1-induced cell death appears to be mainly 'non-apoptotic', which has been named 'programmed necrosis' (157, 158) , although several studies have suggested that PARP-1 activation can also mediate apoptosis under certain conditions (159, 160) .
Increasing evidence has indicated close interactions among PARP-1, calpains and caspase-3. There are several lines of evidence indicating that PARP-1 and caspase-3 is each other's lethal enemy: Excessive PARP-1 activation can prevent caspase-3 activation by depleting ATP, and could block the activation of caspase 3-dependent DNA fragmentation factors DFF40 (161) . Vice versa, PARP-1 is a known substrate for caspase-3-dependent cleavage that abolishes PARP-1 activity (156) . It has also been found that the caspase 3-produced Nterminus cleavage product of PARP-1 can promote UVmediated apoptosis by preventing ATP depletion (162) . The mutual killing relationship between caspase-3 and PARP-1 may be explained as follows: Increasing evidence has indicated caspase-3 and PARP-1 as the key mediators of apoptosis and 'programmed necrosis', respectively. Because these two enzymes could be the master mediators of these death modes, the mutual inhibition of caspase-3 and PARP-1 may be needed to ensure uninterrupted execution of a specific cell death cascade. Several studies have further deepen our understanding about the interplays between caspase-3 and PARP-1: The study by Garnier et al. showed that caspase-3-dependent cleavage of PARP-1 could mediate ischemic preconditioning (163); and PARG was also found to be a substrate of caspase-3 (164).
The significant interactions among calpains, PARP-1 and caspase-3 are indicated by the following findings: First, both PARP-1 and procaspase-3 can be cleaved by calpains that are, like caspase-3, cysteinedependent proteases (165) . The cleavage was found to produce inhibition of PARP-1 and caspase-3 (165); second, caspase 3 can degrade calpastatin ---the endogenous calpain inhibitor, leading to activation of calpains (156, 166) ; and third, PARP-1 activation may lead to calpain activation by TRPM2-dependent increases in intracellular Ca 2+ concentrations (55) (56) (57) .
Based on the above discussion, it is tempted to propose that under a majority conditions, PARP-1, caspase-3 and calpains may be three master mediators of three cell death modes ---'programmed necrosis', apoptosis, and mixed-type cell death. The complex interactions among these 'master mediators' may be the pivotal events in deciding cell death modes. Future studies are warranted to determine the mechanisms that mediate these complex interactions under various pathological conditions.
Potential roles of NAD
+ and NADH in apoptosis Cumulative evidence has suggested that NAD + and NADH may play important roles in apoptosis: NADH / NADPH depletion has been found to be a very early event in apoptosis (167) . It has also been reported that selective inhibitors of NAD + synthesis can induce apoptosis (84). NAD + and NADH may affect apoptosis through several potential mechanisms: First, NADH / NAD + ratio is a major index of cellular reducing power, which can modulate MPT ---a mediator of apoptosis under many conditions (36) . Second, NAD + and NADH also play a key role in cellular energy metabolism that is a critical factor determining cell death modes. Third, NAD + levels mediate the activity of caspase-dependent endonuclease DFF40---a key executioner of DNA fragmentation in apoptotic cascade (68) . Fourth, NAD + -dependent sirtuins may mediate apoptosis (168) . In contrast to the extensiveness of the studies on PARP-1 ---a mediator of programmed necrosis (157, 158) , there have been much less studies regarding the roles of NAD + and NADH in apoptosis. Future studies on this topic are critical for our comprehensive understanding about the roles of NAD + and NADH in cell demise.
Distinct properties of NADH in cell death
Although NAD + and NADH are extremely closely related, NADH appears to have multiple distinct properties compared with NAD + : First, while NAD + is not permeable to mitochondrial membranes, increased cytosolic NADH can lead to increased NADH in mitochondria through the action of NADH shuttles (1), which may increase mitochondrial membrane potential thus preventing MPT. Second, increased NADH can enhance NADH / NAD + ratio -an index of reducing potential, which may block MPT (36) .
Third, cytochrome oxidase can directly use extramitochondrial NADH to increase mitochondrial membrane potential (38) . Fourth, NADH can directly interact with VDAC, a major component of MPT pore (37) .
With a ratio of cytosolic NAD + / NADH as high as 700 to 1, it is likely that NADH, like intracellular Ca 2+ , is very tightly regulated in cells. In other words, cells could be sensitive to the changes of cytosolic NADH. There is evidence suggesting that both marked decreases and increases in cytosolic NADH may produce detrimental effects: NADH / NADPH depletion was found to be a very early event in apoptosis (167) . While a decreased NADH / NAD + ratio can lead to decreased reducing potential in cells, a high cytosolic NADH level may also exacerbate oxidative damage by inducing iron release from ferritin and by providing substrates for NAD(P)H oxidase and xanthine oxidase / xanthine dehydrogenase (69) to generate ROS. Similarly, while increased cytosolic NADH can lead to increased NADH in mitochondrial via the NADH shuttles thus promoting oxidative phosphorylation, the increased cytosolic NADH may also block oxidative phosphorylation by promoting conversion of pyruvate to lactate, and by inhibiting VDAC permeability. Collectively, increasing evidence appears to suggest that the biological effects of altered cytosolic NADH levels are particularly complicated. These highly complex and intriguing effects of altered cytosolic NADH levels on cell injury should be further investigated.
Our recent study has indicated that NADH treatment decreases PARP-1-mediated astrocyte death with a significantly different dose response compared with that of NAD + treatment (30). The minimal protective doses for NADH and NAD + were 10 µM and 1 milimolar, respectively. However, at concentrations greater than 0.5 milimolar, the protective effects of NADH started to decline, while the NAD + -produced protective effects dose-dependently increased at NAD + concentrations between 1 -10 milimolar. While the exact mechanisms underlying these observations remain unclear, it is possible that excessively increased cytosolic NADH levels produced by high concentrations of extracellular NADH may lead to cytotoxicity via such mechanisms as inducing reductive stress, inhibiting VDAC and converting pyruvate to lactate.
THERAPEUTIC POTENTIAL OF NAD
+ 7.1. In vitro studies have suggested therapeutic potential of NAD + and NADH The recent studies by our research group have provided first evidence indicating that extracellularly applied NAD + and NADH can significantly decrease PARP-1 cytotoxicity (18, 24, 29, 30). It has also been shown that extracellular NAD + can prevent transactioninduced axonal injury, while the role of SIRT1 in this protection remains controversial (16, 169) . These results raise the possibility that NAD + and NADH may be used in vivo to decrease PARP-1-mediated tissue injury. This possibility has been further enhanced by the observations that NAD + levels are significantly decreased by a PARPmediated mechanism in the brains subjected to ischemiareperfusion (100, 170) , and the excitotoxin glutamate decreases NADH / NAD + ratios in a brain slice model (171).
Limitations of PARP inhibitors as potential therapeutic agents
While many studies have shown that PARP inhibitors can decrease cell injury under various pathological conditions (17), some studies have suggested that PARP inhibitors may also produce toxic effects. One of the major problems for PARP inhibitors in treating PARP-1-related diseases is: PARP-1 is a key enzyme for repairing single-strand DNA damage (15). While PARP-1 inhibition can decrease cell injury by preventing NAD + depletion, this inhibition could also compromise DNA repair capacity of cells. Because it is known that DNA damage can induce cell death by activating multiple cell death-inducing pathways such as that mediated by p53, PARP inhibitors may produce significant toxic side effects. As reported by Nakayama et al., PARP inhibitors can lead to increased ischemic brain injury in a model of mild brain ischemia (172) . PARP inhibitors also promote γ irradiation-induced neuronal death (173) . Our recent study has shown that the PARP inhibitor DPQ can not decrease peroxynitriteinduced DNA damage when applied either before or after peroxynitrite treatment (174) . Because PARP-1 is also important for neurotrophic effects of nerve growth factor (175), learning and memory (176, 177) , and regulation of gene expression, cell cycle progression and genomic stability (15), it is conceivable that PARP inhibitors may produce multiple unwanted side effects. Thus, it is of great clinical significance to find new approaches that can not only decrease PARP-1 toxicity at more delayed time points by blocking PARP-1-mediated downstream events, but also avoid the toxic effects produced by direct PARP-1 inhibition. Our latest studies have suggested that NAD + administration may be one of these novel approaches.
7.3.
In vivo studies have suggested the therapeutic potential of NAD + for PARP-1-mediated diseases One of the major concerns for drug delivery into the brains is that the drug delivery is often significantly limited by blood-brain barriers (178) . A number of studies, including our own studies, have found that the drug delivery by the intranasal approach can produce neuroprotective effects in several brain disease models (179) . This approach could have the following merits over traditional approaches: First, it may deliver drugs into the brains by bypassing blood-brain barriers, which is one of the major obstacles for treating brain diseases; second, it could reduce the probability that the protective effects of certain drugs on the CNS may result from the drug effects on peripheral systems; and third, it may decrease the amount of drugs needed to affect CNS, which could significantly decrease the cost of treatments. Notably, our study has shown that intranasal delivery of gallotannin (GT), a PARG inhibitor (135, 136), was dramatically more effective than i.v. injection of GT in decreasing ischemic brain damage (180) : GT can decrease infarct formation by at least 50% even when administered 5 hrs after ischemic onset, while i.v. injection of GT did not produce significant protective effects even when administered immediately after reperfusion.
Based on this information, we applied intranasal delivery approach in delivering NAD + into the brains to test our hypothesis that NAD + may be used to decrease ischemic brain damage (181) . We found that intranasal administration with NAD + is capable of increasing NAD + levels in rat brains. In a rat model of 2-hour transient focal ischemia, intranasal administration with 10 -20 mg / kg NAD + at 2 hr after ischemic onset can decrease infarct formation and neurological deficits by greater than 80%. These results suggest that NAD + may be used as a novel therapeutic agent for treating cerebral ischemia and other PARP-1-mediated diseases.
PERSPECTIVES
Increasing evidence has suggested that NAD + and NADH play critical roles not only in energy metabolism and mitochondrial functions, but also in cell death, aging and most of the major cellular functions. These findings have fundamental changed our understanding about NAD + and NADH, suggesting the critical importance of these molecules in various aspects of life.
Numerous studies have indicated that ATP and Ca 2+ play particularly important roles in virtually every major biological activities as well as in cell death and aging: Intracellular Ca 2+ mediates numerous biological processes such as muscle contraction, neurotransmitter release, learning and memory as well as cell death (83, 106, (182) (183) (184) (185) (186) ; similarly, ATP not only acts as the basic energy molecule for most biological processes, but also mediates signal transduction by acting as the substrate for numerous protein kinases and acting as a crucial extracellular signaling molecule (1, 47, 187 (83, 106, (182) (183) (184) (185) (186) .
During the last 10 years our understanding about NAD + and NADH has been dramatically improved, which may be exemplified by the numerous critical findings about PARPs and sirtuins. It is expected that our understanding about NAD + and NADH would be further rapidly improved, considering that many crucial questions in this field still remain unanswered. It is conceivable that future studies would further establish the roles of NAD + and NADH as fundamental mediators of cell death, aging and various biological functions. Our solid grasp of the biological properties of these molecules would be not only critical for answering some fundamental questions about life, but also essential for novel strategies for slowing aging and treating many diseases.
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